Compare Indokem with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 4.51%
- Poor long term growth as Net Sales has grown by an annual rate of 13.02% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.94 times
Flat results in Dec 25
With ROCE of 8.8, it has a Very Expensive valuation with a 24.3 Enterprise value to Capital Employed
Despite the size of the company, domestic mutual funds hold only 0.31% of the company
Stock DNA
Specialty Chemicals
INR 1,961 Cr (Micro Cap)
376.00
31
0.00%
0.32
8.95%
30.43
Total Returns (Price + Dividend) 
Indokem for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Indokem Ltd is Rated Sell by MarketsMOJO
Indokem Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleAre Indokem Ltd latest results good or bad?
Indokem Ltd's latest financial results for Q3 FY26 reveal significant challenges in its operational performance. The company reported net sales of ₹42.02 crores, which reflects a modest sequential growth of 4.27% compared to the previous quarter but a decline of 3.18% year-on-year from ₹43.40 crores in Q3 FY25. This indicates a struggle to maintain revenue levels amidst a challenging market environment. The most concerning aspect of the results is the sharp decline in operating profitability, with the operating profit margin (excluding other income) falling to 0.43%, down from 3.25% in the same quarter last year. This marks the lowest operating margin recorded in recent quarters, highlighting increasing pressure on the company's core manufacturing operations, particularly in the textile chemicals sector, which has faced headwinds due to weak demand and rising costs. Net profit for the quarter stood at ₹0....
Read full news article
Indokem Q3 FY26: Profitability Under Pressure as Operating Margins Collapse to 0.43%
Indokem Limited, a speciality chemicals manufacturer within the Khatau Mahendra Group, reported a consolidated net profit of ₹0.41 crores for Q3 FY26 ended December 2025, remaining virtually flat sequentially whilst declining 44.59% year-on-year from ₹0.74 crores in Q3 FY25. The ₹2,080-crore market cap company witnessed its stock trading at ₹734.05 as of January 30, 2026, down 0.30% on the day, reflecting investor caution following the subdued quarterly performance.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
31-Jan-2026 | Source : BSEPursuant to Regulation 47 of the SEBI (LODR) Regulations 2015 we enclose herewith copies of the newspaper cutting extracts of Unaudited Financial Results for the Quarter and Nine months ended 31st December 2025 as approved by the Board of Directors of the Company in its meeting held on Friday 30th January 2026.
Board Meeting Outcome for Board Meeting Outcome For Meeting Held On 30.01.2026
30-Jan-2026 | Source : BSEPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we hereby inform you that the Board of Directors at its Meeting held today has approved the matter as mentioned in the enclosed intimation.
Results- Financial Results For The Quarter Ended 31St December 2025
30-Jan-2026 | Source : BSEThe unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31st December 2025 were approved by the Board of Directors at its meeting held today. Results are enclosed with this intimation.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 10 Schemes (0.1%)
Held by 0 FIIs
Vindhyapriya Holdings Pvt Ltd (19.76%)
Sangeetha S (1.79%)
25.95%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -3.18% vs 7.80% in Dec 2024
YoY Growth in quarter ended Dec 2025 is -44.59% vs 628.57% in Dec 2024
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 1.99% vs -5.01% in Sep 2024
Growth in half year ended Sep 2025 is 180.43% vs 72.67% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.18% vs -0.87% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 337.50% vs 87.67% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 8.06% vs 47.33% in Mar 2024
YoY Growth in year ended Mar 2025 is 151.21% vs -2,096.77% in Mar 2024






